Jessica Royce, APRN
Family · Milton, FLNPI 1609244383
Payments from drug & device makers
Across 218 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$629
- AbbVie$517
- Novo Nordisk$454
- Pfizer$430
- GSK$279
- Lilly USA, LLC$262
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,744100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $629 |
| AbbVie | 38 | $517 |
| Novo Nordisk | 25 | $454 |
| Pfizer | 22 | $430 |
| GSK | 18 | $279 |
| Lilly USA, LLC | 16 | $262 |
| Bayer | 9 | $204 |
| Amgen | 12 | $189 |
| Exact Sciences | 8 | $122 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $90 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $65 |
| Merck | 4 | $62 |
| Biohaven Pharmaceuticals, Inc. | 4 | $53 |
| Boehringer Ingelheim | 2 | $45 |
| Abbott | 3 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $45 |
| Johnson & Johnson | 3 | $44 |
| Shield Therapeutics Inc | 2 | $39 |
| Corium, LLC | 1 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Dexcom, Inc. | 1 | $24 |
| Verona Pharma, Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Tris Pharma Inc | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$3,744 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $73,692 |
| MounjaroTirzepatide | 38 | $54,309 |
| FarxigaDapagliflozin Propanediol | 49 | $49,476 |
| EliquisApixaban | 36 | $39,677 |
| TrulicityDulaglutide | 24 | $36,335 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $27,389 |
| JardianceEmpagliflozin | 18 | $20,779 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $13,137 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $12,662 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $7,934 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $5,358 |
| Novolog FlexpenInsulin Aspart | 16 | $4,036 |
| Atorvastatin Calcium | 387 | $3,127 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 126 | $3,106 |
| Omeprazole | 191 | $2,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $262 | $90,64462 claims |
| Novo NordiskOzempic | $454 | $73,69243 claims |
| AstraZenecaFarxiga, Symbicort | $629 | $62,13881 claims |
| PfizerEliquis | $430 | $39,67736 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $279 | $35,32358 claims |
| Boehringer IngelheimJardiance | $45 | $20,77918 claims |
| AbbVieSynthroid | $517 | $2,27520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Milton
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.